Analysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) PT at $35.92

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have earned a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $35.9167.

Several equities analysts have recently issued reports on DNLI shares. JPMorgan Chase & Co. initiated coverage on Denali Therapeutics in a research note on Monday, July 13th. They set an “overweight” rating and a $29.00 target price on the stock. Deutsche Bank Aktiengesellschaft raised their price target on Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, UBS Group raised their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, August 7th.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the sale, the insider directly owned 281,763 shares in the company, valued at $7,063,798.41. This trade represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 9.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in DNLI. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Denali Therapeutics in the 2nd quarter valued at approximately $26,000. Headlands Technologies LLC purchased a new stake in Denali Therapeutics in the second quarter worth $26,000. Global Retirement Partners LLC purchased a new stake in Denali Therapeutics in the second quarter worth $28,000. Johnson Financial Group Inc. bought a new position in Denali Therapeutics in the third quarter worth $29,000. Finally, State of Wyoming bought a new position in Denali Therapeutics in the second quarter worth $29,000. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $24.40 on Friday. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. The firm has a market cap of $3.90 billion, a P/E ratio of -8.59 and a beta of 1.01. Denali Therapeutics has a 1-year low of $12.58 and a 1-year high of $27.30. The firm has a 50-day moving average of $24.04 and a 200-day moving average of $21.48.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. During the same quarter in the previous year, the company posted ($0.72) EPS. Sell-side analysts expect that Denali Therapeutics will post -2.59 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics is a clinical?stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine?rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti?TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.